Open AccessA review of the latest research on Mpro targeting SARS-COV inhibitors
Author(s) -
Huihui Yang,
Jinfei Yang
Publication year - 2021
Publication title -
rsc medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 55
ISSN - 2632-8682
DOI - 10.1039/d1md00066g
Subject(s) - covid-19 , drug development , pandemic , coronavirus , highly pathogenic , virology , protease , drug , drug discovery , medicine , outbreak , biology , virus , pharmacology , bioinformatics , infectious disease (medical specialty) , enzyme , disease , biochemistry , pathology , influenza a virus subtype h5n1
Since the outbreak of COVID-19, the pandemic caused by SARS-CoV-2 infection is still spreading at an alarming rate and has caused huge loss of life and economic damage worldwide. Although more than one year has passed, effective treatments for COVID-19 and other pathogenic coronaviruses have not yet been developed. Therefore, the development of SARS-CoV-2 inhibitors is an urgent priority. Given that the M pro sequences of SARS-CoV-2 and SARS-CoV-1 are 100% identical in the catalytic domain for protein cleavage, the viral main protease (M pro ) is one of the most extensive drug targets in all the drug targets being investigated for SARS-CoV-2. To provide scientific researchers with timely anti-SARS-CoV drug development information for M pro , we focus on the past and current drug design and development strategies for M Pro in this review. We believe that this review will provide meaningful guidance for the design and development of innovative drugs against COVID-19 and other pathogenic coronaviruses in the future.